Partners
We work with world-renowned pharmaceutical organizations such as Biomarin, Recordati Rare diseases, PTC Therapeutics, etc. They help us provide the patients the quality medicines and deliver hard-to-access drugs to needy patients to improve their quality of life.
Big thinking for people with rare diseases
Ikris Pharma helps in accessing Recordati Rare Disease medicines for patients in India, Nepal, Pakistan & Sri Lanka through strategic alliances and exclusive distribution agreement. Patients from above mentioned countries can directly contact Ikris for Orphan Europe products.
Translating Science Transforming Lives
Ikris Pharma Network is authorized by PTC Therapeutics to provide access to their medicines to Indian patients through Named-Patient Import.
We help to drive therapeutic progress
Ikris Pharma Network is authorized by Servier to provide access to their medicines to Indian patients through Named-Patient Import.
Treatment is only the beginning
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions. Ikris Pharma Network is authorized by BioMarin to provide access to the company’s medicines to Indian patients through Named-Patient Import. For more information, click here to visit BioMarin's official website.
Advancing the promise of precision genetic medicine
Ikris Pharma Network is authorized by Sarepta Therapeutics to provide access to their medicines to Indian patients through Named-Patient Import.
Every Day Builds a Better Tomorrow
Ikris Pharma Network is authorized by Alexion Pharmaceuticals to provide access to Asfotase Alfa to Indian patients through Named-Patient Import basis.
Focused on Rare and Neuromuscular Conditions
Ikris Pharma Network has received official authorization from Santhera Pharmaceuticals to facilitate patient access to their medicines for Duchenne Muscular Dystrophy (DMD) in India. Through the Named-Patient Import pathway, physicians can legally request treatment for eligible patients, ensuring compliance with Indian regulatory requirements. For more information, click here to visit Santhera's official website.
Advancing Access in Metastatic Breast Cancer
Ikris Pharma Network has been authorized by Gilead Sciences, Inc. to support patient access to specific therapies for HR+/HER2- metastatic breast cancer and metastatic triple-negative breast cancer in India. Access will be facilitated through the Named-Patient Import pathway, which allows physicians to legally request these medicines for eligible patients in accordance with Indian regulatory requirements. For more information, click here to visit Gilead Sciences' official website.
Ikris Partnership Program
Join us in
forging impactful partnerships for a brighter future!
Join us for innovative collaboration, cutting-edge research, and global healthcare impact. Together, we’ll advance medical science and improve lives.
